title: Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients.
abstract: BACKGROUND
  Interferon (IFN) therapy, an antiviral agent, contributes to the prevention of occurrence of hepatocellular carcinoma (HCC) and to improvement in long-term prognosis. However, IFN therapy is not well-implemented in Japan. The present study was conducted to analyze factors preventing the implementation of IFN therapy.
  
  
  METHODS
  Questionnaires were sent to patients with hepatitis C virus (HCV)-related liver disease who were treated at 7 clinics (by non liver-specialists) and 1 hospital (by liver specialists) and by their attending physicians.
  
  
  RESULTS
  Of 139 patients for whom attending physicians recommended IFN therapy, 92 (66.2%) agreed to receive the treatment. The proportions of patients who agreed to receive IFN therapy were 74 (86.0%) out of 86 hospital patients and 18 (34%) out of 53 clinic patients. In logistic regression analysis, the adjusted odds ratios on treatment facilities, sex and complications were 18.06, 3.65, and 3.63 respectively, indicating that there were significant differences. Female patients more than male patients declined IFN therapy because of worries over the adverse reactions of IFN therapy.
  
  
  CONCLUSIONS
  Multivariate analysis showed that factors contributing to the risk that a patient would not consent to receive IFN therapy included a) treatment facilities, b) sex, and c) the presence or absence of complications. It is also essential to devise measures to create cooperation between hospitals and clinics, and to improve communication between physicians and patients.
authors.affiliation: Department of Digestive Disease Information and Research, Kurume University School of Medicine, Kurume, Fukuoka, Japan. nagao@med.kurume-u.ac.jp
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Nagao
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Yoshiyama
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
chemical_list: D007372:Interferons